Antitumour activity of DX-8951f: a new camptothecin derivative
- 1 April 1998
- journal article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 7 (4), 625-632
- https://doi.org/10.1517/13543784.7.4.625
Abstract
DX-8951f is a water-soluble camptothecin analogue with a unique hexacyclic structure. Compared to other current camptothecin derivatives, DX-8951f is the most effective topoisomerase I (topo I) inhibitor and has the most potent cytotoxic activity against various tumour cell lines in vitro. Of particular interest is DX-8951f's significant effect on certain tumour cell lines resistant to other camptothecin derivatives, as well as on multi-drug resistant variants that overexpress P-glycoprotein. In addition, in in vivo xenograft systems using nude mice, DX-8951f strongly inhibits the growth of human solid tumours, including resistant tumours. Its antitumour effects and resulting life prolongation in tumour-bearing mice have also been confirmed in several metastasis models. DX-8951f provides greater therapeutic efficacy and broader effective dose ranges using multiple injections than with a bolus injection and simple intermittent applications. The in vivo effects of the compound are superior to those of CPT-11 and SK&F104864, suggesting that DX-8951f is a promising therapeutic agent for the treatment of cancer patients. Phase I clinical trials are ongoing in Europe, the USA and Japan.Keywords
This publication has 16 references indexed in Scilit:
- Establishment and characterization of human gastric and colonic xenograft lines resistant to CPT-11 (A new derivative of camptothecin)Journal of Surgical Oncology, 2006
- Antitumor Effect of DX‐8951, a Novel Camptothecin Analog, on Human Pancreatic Tumor Cells and Their CPT‐11‐resistant Variants Cultured in vitro and Xenografted into Nude MiceJapanese Journal of Cancer Research, 1997
- A New Water‐soluble Camptothecin Derivative, DX‐8951f, Exhibits Potent Antitumor Activity against Human Tumors in vitro and in vivoJapanese Journal of Cancer Research, 1995
- Apoptosis of Lung Cancer Cells Caused by Some Anti-cancer Agents (MMC, CPT-11, ADM) is Inhibited by BCL-2Biochemical and Biophysical Research Communications, 1993
- The Current Status of Camptothecin Analogues as Antitumor AgentsJNCI Journal of the National Cancer Institute, 1993
- Activity of Topotecan, a New Topoisomerase I Inhibitor, Against Human Tumor Colony-Forming Units In VitroJNCI Journal of the National Cancer Institute, 1992
- Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell lineBiochemical and Biophysical Research Communications, 1992
- Differential expression of DNA topoisomerase I gene between CPT-11 acquired-and native-resistant human pancreatic tumor cell lines: Detected by RNAPCR-based quantitation assayBiochemical and Biophysical Research Communications, 1992
- Phase I Study of Weekly Intravenous Infusions of CPT-11, a New Derivative of Camptothecin, in the Treatment of Advanced Non-Small-Cell Lung CancerJNCI Journal of the National Cancer Institute, 1991
- MECHANISMS OF MULTIDRUG RESISTANCE AND IMPLICATIONS FOR THERAPYJapanese Journal of Cancer Research, 1988